Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer

PRIMARY OBJECTIVES: I. Assess diffusion-weighted MRI as an early predictor for tumor response in patients with non-small cell lung cancer (NSCLC). II. Establish the potential of individualized radiotherapy targeting of radioresistant tumor sub-volumes. OUTLINE: Patients undergo diffusion-weighted MRI within 4 weeks of radiation start (baseline), during the second week of radiation therapy, during the fourth week of radiation therapy, and at 3 months after radiation therapy (post-treatment). Patients also undergo standard of care 4-dimensional (4D) computed tomography (CT) and fludeoxyglucose F 18 (FDG)-positron emission tomography (PET) at the same time points.